<< Read Full Article
<< Read Full Article
ImClone Falls on Erbitux Sales
- Loading Comments...
Shares of ImClone Systems(IMCL Quote) dropped Monday after analysts noticed that U.S. sales of the company's colon cancer drug Erbitux were lower in July.
Recently, ImClone's stock had lost $4.02, or 7.2%, to $51.98.
The dip in U.S. sales to $25.4 million in July vs. $30.1 million in June "is a cause of concern, but not for alarm," said Corey Kasimov of Oppenheimer in a brief note to clients Monday. The sales are tracked by IMS Health. ...
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,270.02 | 1,088.86 | 2,163.05 | 33.77 |
Oil *
75.40
|
|
DOWN
15.95
|
DOWN
3.07
|
DOWN
9.94
|
DOWN
0.15
|
10 Yr
3.38%
SPDR Gold
111.56
|
|
-0.16%
|
-0.28%
|
-0.46%
|
-0.44%
|
Data delayed 20 minutes |


Connect with TheStreet